Anupam Rasayan eyes US, Europe pharma push after Bliss deal, one-third revenue from drugs

Anupam Rasayan India Ltd anticipates significant growth in its pharmaceutical segment over the next three years. The company expects pharmaceuticals to comprise one-third of overall revenue driven by the acquisition of Bliss GVS Pharma. Anupam’s ability to offer integrated contract manufacturing…

Khabar Adda curates headlines like this across Top Stories, Entertainment, Bollywood, Hollywood, Crime and Politics from public RSS feeds. This page links out to economictimes.indiatimes.com's own reporting rather than reproducing it — the excerpt above comes from economictimes.indiatimes.com's own feed.